A coronavirus vaccine from Germany’s BioNTech has yielded positive trial results, generating immune defences in participants that were stronger than those of the average recovered Covid-19 patient, according to preliminary data released by the company.
據德國製藥公司BioNTech發佈的初步數據，該公司的一種新型冠狀病毒疫苗在試驗中取得了積極的結果，受試者所產生的免疫防禦能力要強於新型冠狀病毒肺炎（COVID-19，即2019冠狀病毒病）康復患者的平均抗體水準。
您已閱讀6%（359字），剩餘94%（5978字）包含更多重要資訊，訂閱以繼續探索完整內容，並享受更多專屬服務。